Retatrutide is a multi-receptor agonist peptide that supports significant weight loss and metabolic improvements. It is typically administered via subcutaneous injection once weekly, with doses gradually increasing over several weeks to enhance tolerability and efficacy. The protocol often spans 12 to 24 weeks or longer.
- Triple-agonist targeting GLP-1, GIP, and glucagon receptors.
- Achieved average weight loss of 22-24% in clinical trials.
- Administered once weekly via subcutaneous injection.
- Gradual dose escalation is crucial to minimize GI side effects.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
1 mL
Concentration
10 mg/mL
1 unit = 0.01 mL = 100 mcg
- 1Carefully draw 1.0 mL of bacteriostatic water using a sterile syringe.
- 2Inject the water slowly down the inside wall of the Retatrutide vial to prevent foaming.
- 3Gently swirl or roll the vial until the powder is completely dissolved; avoid shaking.
- 4Clearly label the reconstituted vial with the date and store it in the refrigerator at 2-8 °C (35.6-46.4 °F), protected from light.
- 5Ensure to use the reconstituted solution within 4 weeks.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-4 | 2 mg | 20 units (0.20 mL) |
| Weeks 5-8 | 4 mg | 40 units (0.40 mL) |
| Weeks 9-12 | 6 mg | 60 units (0.60 mL) |
| Weeks 13+ | 8 mg | 80 units (0.80 mL) |
Protocol detail
| Start | Begin with 2 mg weekly for 4 weeks to evaluate individual tolerance. |
|---|---|
| Escalate | Increase the dose by 2–4 mg every 4 weeks, provided it is well tolerated. |
| Target | Aim for a standard weekly dose of 6–8 mg, or up to 12 mg for advanced/aggressive protocols. |
| Frequency | Administer once per week via subcutaneous injection, ideally on the same day each week. |
| Cycle Length | A minimum cycle duration of 24 weeks is recommended, with trials extending to 48 weeks. |
| Timing | Injections can be administered at any consistent day and time, with rotation of injection sites for each dose. |
Overview at a glance
| Goal | Support substantial weight reduction and enhance metabolic health by activating triple receptors. |
|---|---|
| Schedule | Subcutaneous injections performed weekly for 12 to 48 weeks, mirroring durations in clinical trials. |
| Dose Range | Weekly doses of 2–12 mg, with gradual escalation steps every four weeks. |
| Reconstitution | Add 1.0 mL of bacteriostatic water per 10 mg vial, yielding approximately 10.0 mg/mL, for precise unit measurement. |
| Storage | Lyophilized form is stored frozen at -20 °C (-4 °F); once reconstituted, refrigerate at 2-8 °C (35.6-46.4 °F) for up to four weeks. |
How it works
Retatrutide uniquely acts as a triple-agonist, engaging GLP-1, GIP, and glucagon receptors. This multi-pronged approach stimulates insulin release in the presence of glucose, curbs appetite, and boosts metabolic rate, promoting energy expenditure. The peptide is modified with a fatty-acid component, extending its half-life to about six days, thus enabling convenient once-weekly dosing. The combined activation of these hormonal pathways leads to reduced calorie intake, enhanced feelings of fullness, and increased fat oxidation, resulting in significant weight loss and improved glycemic control. This strategy effectively counteracts the body's natural metabolic slowdown during weight loss, offering superior efficacy compared to therapies targeting fewer receptors.
Reported effects
- Exceptional body weight reduction (22–24% observed in trials).
- Improved glycemic control, with HbA1c reductions of 1.3–2.0% in T2D.
- Significant cardiometabolic benefits, including lower blood pressure and LDL cholesterol.
- Reductions in waist circumference and liver fat content.
- High response rate, with 100% of participants achieving at least 5% weight loss at higher doses.
Reported side effects
- Common gastrointestinal issues: nausea, vomiting, and diarrhea.
- Side effects are typically mild-to-moderate and occur mainly during dose increases.
- Gradual dose titration significantly reduces GI discomfort.
- No severe hypoglycemia or serious treatment-related adverse events reported in studies.
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) or colder in dry, dark conditions; stable for up to 24 months.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F); use within 4 weeks. Allow vials to reach room temperature before opening. For extended storage, aliquot and freeze at -20 °C (-4 °F), thaw once before use.
Supplies
| Peptide vials | 10 mg each: 5 vials for 12 weeks (standard to 6 mg), 15 vials for 24 weeks (standard to 8 mg), or 6 vials for 12 weeks (aggressive to 8 mg). |
|---|---|
| Insulin Syringes (U-100, 1 mL capacity) | 1-2 syringes per week depending on dose; 12-24 for 12 weeks, 24-48 for 24 weeks. |
| Bacteriostatic Water (10 mL bottles) | ~1.0 mL per vial for reconstitution; 1 x 10 mL bottle for 12 weeks (5 vials), 2 x 10 mL bottles for 24 weeks (15 vials). |
| Alcohol Swabs | 2-4 swabs per week; 1 x 100-count box for 12-24 weeks. |
Important notes
- Always use a new, sterile insulin syringe for each injection and dispose of it properly in a sharps container.
- Rotate injection sites regularly (abdomen, thighs, upper arms) to prevent irritation or lipohypertrophy.
- If the dose requires more than 1.0 mL of reconstituted solution, prepare multiple vials and split the injection into two separate sites for better absorption.
- Inject slowly and wait a few seconds before withdrawing the needle to ensure the full dose is delivered.
- Consistent documentation of doses, dates, and injection sites is recommended.
- Gradual dose titration is key to minimizing gastrointestinal side effects; avoid skipping escalation steps.
Frequently asked questions
How long does it take to see results with Retatrutide?
Clinical trials show significant weight loss can be observed over 12 to 48 weeks, with substantial reductions beginning after the initial weeks of titration and continuing throughout the treatment period. Individual results may vary based on adherence and lifestyle factors.
What should I do if I miss a weekly dose?
If a dose is missed, it should be taken as soon as remembered, provided it is not too close to the next scheduled dose. If it's almost time for the next dose, skip the missed one and continue with the regular schedule. Do not double the dose to compensate for a missed one.
Is Retatrutide safe to use long-term?
Phase 2 clinical trials have evaluated Retatrutide for up to 48 weeks with a safety profile comparable to other incretin-based therapies when properly titrated. Always consult with a healthcare professional before considering long-term use, as research is still ongoing and it is not yet FDA-approved.
Can I combine Retatrutide with other weight loss medications?
Combining Retatrutide with other weight loss medications is not generally recommended without medical supervision due to potential interactions and increased risk of side effects. Always discuss any concurrent medications or supplements with a healthcare provider.
Educational reference only. These figures summarise how Retatrutide is commonly described in research literature and supplier documentation, including the Retatrutide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Retatrutide (30 mg Vial)
Triple-agonist peptide for substantial weight loss and metabolic health.
Retatrutide (40 mg Vial)
Triple-agonist peptide for substantial weight loss and metabolic health.
Retatrutide (5 mg Vial)
Triple-agonist peptide for substantial weight loss and metabolic health.
Retatrutide (20 mg Vial)
Triple-agonist peptide for substantial weight loss and metabolic health.